NDAORAL-28TABLET
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TRI-NORINYL 28-DAY (ethinyl estradiol; norethindrone) by Dr. Reddy's Laboratories. Approved for pregnancy. First approved in 1984.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRI-NORINYL 28-DAY is a triphasic oral contraceptive containing ethinyl estradiol and norethindrone approved in 1984. It prevents pregnancy through hormonal suppression of ovulation via estrogen and progestin mechanisms. The product is administered as a 28-day tablet regimen with varying hormone doses across three phases.
LOE Approaching
As a legacy product approaching loss of exclusivity with low linked job count, career opportunities focus on generic optimization and managed care strategy rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on TRI-NORINYL offers limited career growth potential given zero linked job count and LOE-approaching lifecycle status. Roles focus on defensive positioning, generic competition management, and cost optimization rather than innovative product launch or expansion.
Brand Manager
Worked on TRI-NORINYL 28-DAY at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.